European regimen accelerator for tuberculosis
ERA4TB logo


Start Date
End Date
IMI2 - Call 15
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
89 815 600
EFPIA in kind
48 484 443
Associated Partners
69 663 848
Total Cost
207 963 991


Tuberculosis (TB) poses a serious threat to public health worldwide; in 2018 alone, an estimated 10 million people fell ill with the disease and 1.6 million died. The goal of the ERA4TB project is to accelerate the development of a new, more efficient treatment regimen that will help the world to meet the United Nations goal of ending the TB epidemic by 2030.

Today, standard TB treatment consists of a regimen of four drugs and lasts at least six months; for people with drug-resistant TB, treatment lasts even longer. New drugs are added to regimens one by one, meaning that building a new, faster and safer treatment regimen takes a very long time.

ERA4TB plans to drop the sequential approach and instead adopt a parallel pathway, which will allow the project to investigate the safety and efficacy of combinations of over a dozen drug candidates at the same time. By using a standardised approach and studying multiple molecules in parallel, the project hopes to optimise and speed up the development of new drug regimens needed to stop TB in its tracks.

The project will achieve this by creating a world-class ‘platform’ that brings together the expertise, tools and resources needed to accelerate the development of anti-TB drug combinations. The hope is that the platform will continue to operate beyond the end of the project.

ERA4TB is part of the AMR Accelerator programme.

Participants Show participants on map

EFPIA companies
  • Evotec International GMBH, Hamburg, Germany
  • Glaxosmithkline Investigacion Y Desarrollo SL, Tres Cantos, Spain
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Bioaster Fondation De Cooperation Scientifique, Lyon, France
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Consiglio Nazionale Delle Ricerche, Roma, Italy
  • Department of Health, Leeds, United Kingdom
  • Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland
  • Fondation Innovative Medicines For Tuberculosis (Im4tb), Lausanne, Switzerland
  • Forschungszentrum Borstel, Borstel, Germany
  • Institut Pasteur, Paris, France
  • Institut Pasteur De Lille Fondation, Lille, France
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Latvijas Organiskas Sintezes Instituts, Riga, Latvia
  • Lunds Universitet, Lund, Sweden
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Sciensano, Brussels, Belgium
  • Servicio Madrileno De Salud, Madrid, Spain
  • Universidad Carlos Iii De Madrid, Getafe (Madrid), Spain
  • Universidad De Zaragoza, Zaragoza, Spain
  • Universita Degli Studi Di Padova, Padova, Italy
  • Universita Degli Studi Di Pavia, Pavia, Italy
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Critical Path Institute, Limited, Dublin, Ireland
  • Gritsystems As, Dragør, Denmark
  • Imabiotech SAS, Loos, France
  • Qps Netherlands BV, Groningen, Netherlands
  • Synapse Research Management Partners SL, Barcelona, Spain
Associated partners
  • Bill & Melinda Gates Foundation, Seattle, United States
  • Global Alliance For Tb Drug Development Non Profit Organisation, New York, United States
  • University Of Dundee, Dundee, United Kingdom
Third parties
  • Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz, Madrid, Spain
Project coordinator
Juan Jose Vaquero
Universidad Carlos Iii De Madrid